| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS |
Ongoing |
Emicizumab |
3 |
MO39129 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Tranexamic acid for the treatment of gastrointestinal hemorrhage: aninternational randomized, double-blind, placebo-controlled trial" |
Completed |
Tranexamic acid |
3 |
ISRCTN11225767 |
Prince Mohammad bin Abdulaziz hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. |
Completed |
DICLOFENAC POTASSIUM |
BE |
42856 |
Saudi Ajal |
| "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia" |
Completed |
Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) |
3b |
ARA/001/16 |
King Khalid University Hospital (Riyadh) |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial |
Completed |
Luspatercept (ACE 536) |
3 |
ACE-536-B-THAL-001 |
King Khalid University Hospital (Riyadh) |
| Intra Peritoneal Instillation of Ropivacaine with or without Dexmedetomidine for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy. A randomized controlled |
Completed |
Dexmedetomidine |
2 |
version 4 |
King Abdullah Medical City (Makkah) |
| Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis |
Completed |
cholecalciferol |
3 |
E-15-1667 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) |
Completed |
Osimertinib (AZD9291) |
3 |
D5160C00022 |
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study |
Terminated |
haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) |
3 |
Version date Sep-3-2013 |
King Khalid University Hospital (Riyadh) |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Terminated |
Osimertinib (AZD9291) |
3 |
D5160C00007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
